SANES

10.878

+1.15%↑

BBVA

20.2

+1.03%↑

BNP

92.66

+0.53%↑

CABK

11.56

-0.56%↓

INGA

26.88

-0.68%↓

SANES

10.878

+1.15%↑

BBVA

20.2

+1.03%↑

BNP

92.66

+0.53%↑

CABK

11.56

-0.56%↓

INGA

26.88

-0.68%↓

SANES

10.878

+1.15%↑

BBVA

20.2

+1.03%↑

BNP

92.66

+0.53%↑

CABK

11.56

-0.56%↓

INGA

26.88

-0.68%↓

SANES

10.878

+1.15%↑

BBVA

20.2

+1.03%↑

BNP

92.66

+0.53%↑

CABK

11.56

-0.56%↓

INGA

26.88

-0.68%↓

SANES

10.878

+1.15%↑

BBVA

20.2

+1.03%↑

BNP

92.66

+0.53%↑

CABK

11.56

-0.56%↓

INGA

26.88

-0.68%↓

Home・Elenco Azioni・Sartorius Stedim Biotech.

Sartorius Stedim Biotech.

Aperta

SettoreFinanza

175.4 2.57

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

168.9

Massimo

175.6

Metriche Chiave
By Trading Economics
Entrata	41M 88M
Vendite	-11M 762M
P/E Media del settore	62.036 58.236
EPS	1.17
Margine di Profitto	11.569
Dipendenti	10,456
EBITDA	26M 225M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+34.6% upside

Dividendi
By Dow Jones
Utili prossimi	23 lug 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-1.6B 17B
Apertura precedente	172.83
Chiusura precedente	175.4

Notizie sul Sentiment di mercato

By Acuity

21%

79%

37 / 437 Classifica in Finance

Sartorius Stedim Biotech. Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

26 mag 2026, 16:52 UTC

Principali Notizie su Eventi

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26 mag 2026, 23:57 UTC

Utili

Sociedad Quimica 1Q Rev $1.76B >SQM

26 mag 2026, 23:57 UTC

Utili

Sociedad Quimica 1Q EPS $1.28 >SQM

26 mag 2026, 23:48 UTC

Discorsi di Mercato

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26 mag 2026, 21:54 UTC

Utili

Webco Industries 3Q EPS $11.61 >WEBC

26 mag 2026, 21:54 UTC

Utili

Webco Industries 3Q Sales $179.6M >WEBC

26 mag 2026, 21:48 UTC

Discorsi di Mercato

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26 mag 2026, 21:00 UTC

Discorsi di Mercato

ESG Roundup: Market Talk

26 mag 2026, 20:58 UTC

Acquisizioni, Fusioni, Takeovers

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26 mag 2026, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

26 mag 2026, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

26 mag 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

26 mag 2026, 19:22 UTC

Discorsi di Mercato

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26 mag 2026, 19:17 UTC

Discorsi di Mercato

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26 mag 2026, 18:56 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26 mag 2026, 18:03 UTC

Discorsi di Mercato

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26 mag 2026, 17:42 UTC

Discorsi di Mercato

Grains Await Fresh Trading Catalyst -- Market Talk

26 mag 2026, 17:33 UTC

Discorsi di Mercato

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26 mag 2026, 17:21 UTC

Discorsi di Mercato

Canada Faces a Labor Market Squeeze -- Market Talk

26 mag 2026, 16:52 UTC

Discorsi di Mercato

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26 mag 2026, 16:43 UTC

Discorsi di Mercato

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26 mag 2026, 16:24 UTC

Discorsi di Mercato

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26 mag 2026, 16:21 UTC

Discorsi di Mercato

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26 mag 2026, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

26 mag 2026, 16:20 UTC

Discorsi di Mercato

Energy & Utilities Roundup: Market Talk

26 mag 2026, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

26 mag 2026, 16:20 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Auto & Transport Roundup: Market Talk

26 mag 2026, 16:16 UTC

Discorsi di Mercato

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26 mag 2026, 16:01 UTC

Discorsi di Mercato

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26 mag 2026, 15:21 UTC

Discorsi di Mercato

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Confronto tra pari

Modifica del prezzo

Sartorius Stedim Biotech. Previsione

Obiettivo di Prezzo

By TipRanks

34.6% in crescita

Previsioni per 12 mesi

Media 233 EUR 34.6%

Alto 262 EUR

Basso 210 EUR

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Sartorius Stedim Biotech. - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 8 che hanno fornito valutazioni azionarie a Sartorius Stedim Biotech. - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

37 / 437 Classifica in Finanza

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.